Avenzo adds CFO responsibilities to CBO Lipman’s role

Oncology company Avenzo Therapeutics Inc. expanded the role of its CBO, Scott Lipman, to include CFO. Lipman succeeds Paolo Tombesi, who has retired. Before joining Avenzo in March 2023 as SVP, corporate development, Lipman was chief of staff at Turning Point Therapeutics, continuing on at Bristol Myers Squibb (NYSE:BMY) after the pharma acquired it in a strategy and BD role. Backed with nearly $450 million in private funding, Avenzo has expressed an interest in going public.

NovaBridge Biosciences (NASDAQ:NVB), until recently known as I-Mab, named Cadmus Rich CMO of its ophthalmic subsidiary Visara Inc. Rich has been CMO of Lassen Therapeutics Inc. and Aura Biosciences Inc. (NASDAQ:AURA)...